Zeiss
Supplies lithography optics for semiconductor manufacturing
Application Engineer 2
Hybrid role; must live within a commutable distance to Huntersville, NC. Onsite engagements typically 1- to 2-week periods; travel up to 35-50% in the USA and internationally.
About the job
- A four-year degree in Engineering, Math or Physics.
- Alternatively, 3 years of experience in the Metrology industry.
- The AE Level 2 has all the same core requirements of a Level 1 but adds a 3 year minimum experience requirement in the role of Applications Engineer Level 1. Equivalent experience will be considered if hiring from the outside rather than promoting from within.
- Ability to read engineering drawings for dimensional control requirements.
- Ability to operate all types of ZEISS measuring machines including programming using ZEISS application software; setup and staging of parts; accuracy and repeatability verification; etc.
- Strong computer skills and affinity for computer aided data analysis products.
- Must have strong problem-solving skills with the ability to learn independently to find solutions to potential customer’s problems.
- Good verbal and written communication skills with an ability to create concise technical reports.
- Ability to reason and negotiate complex problems with customers.
- Understanding of manufacturing, product development and quality control.
- Ability to work independently and complete tasks under high pressure and tight timelines as needed.
- Proficient at Microsoft 365 and related software packages.
- Meet required qualifications to work with ITAR designated data.
- Ability to lift 50lbs from floor to table height.
- Ability to work flexible hours (nights and weekends).
- Must be a team player across the organization.
- Possession of a valid driver’s license.
- Consult, primarily at customer location, to ensure the successful implementation and on-going use of ZEISS 3D Scanning and CT/Xray solutions.
- Develop customer specific training requirements including on-sight workshops, on-location training, classroom training based on understanding customer needs to ensure the installed solution is successful.
- Interface with customers engineering, quality and manufacturing team members and shop floor personnel to confirm scope of work and make decisions regarding onsite scope changes and adjust deliverables.
- Be the single point contact for collecting and consulting on relevant CAD data provided by the customer.
- Utilize ZEISS solutions to support customers’ automated scanning and inspection of parts and assemblies.
- Consult with customer to create standard operating procedures based on experience to increase other team members knowledge and skills
- Create basic and advanced inspection layouts with reports based on customer requirements.
- Robot cell programming utilizing ZEISS Inspect Pro software.
- Provide customer confidence through accurate and timely deliverables.
- Onsite support, oversight and consultations at customer installations typically consist of 1-to-2-week engagements to assure successful rollouts and customer satisfaction.
- Onsite troubleshoot issues and take or recommend corrective actions or provide appropriate technical information to ZEISS support teams for next step actions.
About the company
Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS SMT opened its Korea Innovation Center in July 2026, deepening customer access.
- July 24, 2026 capacity expansion adds 25,000 square meters in Oberkochen.
- ASML expects 2027 EUV output growth, with Zeiss optics capacity already expanding.
What critics are saying
- ASML bought €4.41 billion from Zeiss in 2025; customer concentration is extreme.
- A prolonged Oberkochen outage would halt ASML production within months.
- Monument Peak sued Zeiss on February 6, 2026 over Kodak patents.
What makes Zeiss unique
- ZEISS SMT remains ASML's sole EUV optics supplier in 2026.
- Oberkochen and Wetzlar are the only places building ASML optical columns.
- High-NA EUV optics from ZEISS anchor sub-2nm lithography for Intel and TSMC.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.
ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.
ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.
ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.
ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.